Barbara L. Weber's most recent trade in Parabilis Medicines Inc. was a trade of 20,215 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 9, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Parabilis Medicines Inc | Barbara L. Weber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2026 | 20,215 | 20,215 | - | - | Stock Option (Right to Buy) | |
| Tango Therapeutics Inc | Barbara L. Weber | Director, Director, Executive Chair | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 222,132 | 222,132 | - | - | Stock Option (Right to Buy) | |
| Tango Therapeutics Inc | Barbara L. Weber | Director, Director, Executive Chair | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 37,522 | 1,659,773 | - | 0 | Common Stock | |
| Tango Therapeutics Inc | Barbara L. Weber | Director, Director, Executive Chair | Sale of securities on an exchange or to another person at price $ 12.26 per share. | 02 Feb 2026 | 30,186 | 1,629,587 | - | 12.3 | 369,999 | Common Stock |
| Tango Therapeutics Inc | Barbara L. Weber | Director, Director, Executive Chair | Sale of securities on an exchange or to another person at price $ 12.90 per share. | 02 Feb 2026 | 333 | 1,629,254 | - | 12.9 | 4,295 | Common Stock |
| Tango Therapeutics Inc | Barbara L. Weber | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2.99 per share. | 04 Feb 2025 | 9,778 | 1,631,264 | - | 3.0 | 29,217 | Common Stock |
| Tango Therapeutics Inc | Barbara L. Weber | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 3.16 per share. | 04 Feb 2025 | 9,013 | 1,622,251 | - | 3.2 | 28,494 | Common Stock |
| Tango Therapeutics Inc | Barbara L. Weber | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 635,250 | 635,250 | - | - | Stock Option (Right to Buy) | |
| Tango Therapeutics Inc | Barbara L. Weber | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2025 | 105,875 | 1,641,042 | - | 0 | Common Stock | |
| Revolution Medicines Inc | Barbara L. Weber | Director | 08 Oct 2024 | 5,200 | 13,065 (0%) | 0% | 48.0 | 249,716 | Common Stock | |
| Revolution Medicines Inc | Barbara L. Weber | Director | 21 Aug 2024 | 1,808 | 18,265 (0%) | 0% | 44.8 | 81,053 | Common Stock | |
| Revolution Medicines Inc | Barbara L. Weber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 16,700 | 16,700 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Barbara L. Weber | Director | 20 Jun 2024 | 15,955 | 15,955 | - | - | Stock Option (Right to Buy) | ||
| Revolution Medicines Inc | Barbara L. Weber | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 4,800 | 20,625 (0%) | 0% | 0 | Common Stock | |
| Revolution Medicines Inc | Barbara L. Weber | Director | 20 Jun 2024 | 4,248 | 20,073 (0%) | 0% | 0 | Common Stock | ||
| Tango Therapeutics Inc | Barbara L. Weber | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 12.56 per share. | 06 Feb 2024 | 4,681 | 1,539,624 | - | 12.6 | 58,806 | Common Stock |
| Tango Therapeutics Inc | L. Weber Barbara | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 12.62 per share. | 06 Feb 2024 | 4,457 | 1,535,167 | - | 12.6 | 56,246 | Common Stock |
| Tango Therapeutics Inc | Barbara L. Weber | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 523,012 | 523,012 | - | - | Stock Option (Right to Buy) | |
| Tango Therapeutics Inc | Barbara L. Weber | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 87,168 | 87,168 | - | 0 | Common Stock | |
| Revolution Medicines Inc | Barbara L. Weber | Director | 08 Jun 2023 | 18,400 | 18,400 | - | - | Stock Option (Right to Buy) | ||
| Revolution Medicines Inc | Barbara L. Weber | Director | 08 Jun 2023 | 5,200 | 15,825 (0%) | 0% | 0 | Common Stock | ||
| Tango Therapeutics Inc | Barbara L. Weber | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 537,273 | 537,273 | - | - | Stock Option (Right to Buy) | |
| Tango Therapeutics Inc | Barbara L. Weber | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 89,545 | 1,457,137 | - | 0 | Common Stock | |
| Revolution Medicines Inc | Barbara L. Weber | Director | 16 Jun 2022 | 18,400 | 18,400 | - | - | Stock Option (Right to Buy) | ||
| Revolution Medicines Inc | Barbara L. Weber | Director | 16 Jun 2022 | 5,200 | 10,625 (0%) | 0% | 0 | Common Stock | ||
| Tango Therapeutics Inc | Barbara L. Weber | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 625,000 | 625,000 | - | - | Stock Option (Right to Buy) |